Allurion Technologies, Inc. ( (ALUR) ) has released its Q1 earnings. Here is a breakdown of the information Allurion Technologies, Inc. presented to its investors.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Allurion Technologies, Inc., a company specializing in metabolically healthy weight loss solutions, is renowned for its innovative Allurion Program, which includes the world’s first swallowable, procedure-less gastric balloon. Operating in the healthcare sector, the company also offers a comprehensive virtual care suite to assist in weight management.
In its first quarter of 2025, Allurion Technologies reported a revenue of $5.6 million, with a significant reduction in operating expenses by 37% compared to the previous year. The company continues to maintain its revenue guidance for 2025 at approximately $30 million while focusing on reducing operating expenses by about 50% compared to 2024.
Key financial highlights include a gross margin increase to 75% from 73% in the prior year and a notable reduction in net operating loss by 36% to $7.3 million. Adjusted operating expenses were reported at $10.1 million, marking a 45% decrease from the previous year. The company also highlighted its successful pre-PMA meeting with the FDA and plans to submit the final module of its PMA by the end of June 2025.
Looking ahead, Allurion Technologies is optimistic about its growth prospects, emphasizing its strategic focus on combining its Allurion Program with low-dose GLP-1 medications. This combination aims to address the shortcomings of GLP-1s by promoting weight loss while maintaining muscle mass, which has garnered interest from healthcare providers and potential partners. The company is set to begin enrolling participants in a prospective trial for this combination approach later this year.